Public Employees Retirement System of Ohio Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• The Public Employees Retirement System of Ohio has made a new investment in Arcturus Therapeutics, purchasing 18,431 shares valued at approximately $240,000.
• Arcturus Therapeutics has seen significant increases in institutional ownership, with 94.54% of its stock now held by institutional investors and hedge funds.
• Despite recent investments, analysts have mixed opinions on the stock, with ratings ranging from a "sell" to "buy," and a current average price target of $50.57.

Public Employees Retirement System of Ohio purchased a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,431 shares of the biotechnology company's stock, valued at approximately $240,000. Public Employees Retirement System of Ohio owned 0.07% of Arcturus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Byrne Asset Management LLC boosted its position in Arcturus Therapeutics by 89.8% during the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 1,365 shares during the period. US Bancorp DE lifted its holdings in shares of Arcturus Therapeutics by 218.9% in the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after buying an additional 2,329 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Arcturus Therapeutics by 3,482.9% in the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after buying an additional 5,085 shares during the period. Strs Ohio acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at $89,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Arcturus Therapeutics by 40,686.2% in the first quarter. Russell Investments Group Ltd. now owns 11,828 shares of the biotechnology company's stock valued at $125,000 after buying an additional 11,799 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ARCT shares. Weiss Ratings restated a "sell (d-)" rating on shares of Arcturus Therapeutics in a report on Saturday, September 27th. Leerink Partners cut their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a report on Friday, August 22nd. Citigroup restated a "buy" rating and issued a $49.00 price objective (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Finally, Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $50.57.

Arcturus Therapeutics Trading Down 6.9%

NASDAQ:ARCT opened at $21.01 on Tuesday. The firm has a market capitalization of $570.63 million, a price-to-earnings ratio of -9.42 and a beta of 2.39. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $24.13. The business's fifty day moving average price is $17.32 and its 200 day moving average price is $14.01.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.77. The firm had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. Equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.